Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Phase 4 Recruiting 4374 enrolled China National Center for Cardiovascular Diseases

RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation.

Timeline

Start: 2024-09-01
Primary completion: 2026-12-31
Completion: 2027-12-31

Publications

Han J, Qi W, Yuan S, Liu H, Wang Y, Zhang H, Liu J, Zhao Y, Zhang Y, Zheng L, Yao Y, Zheng Z. Efficacy and safety of low-dose rivaroxaban in elderly patients with atrial fibrillation for oral anticoagulation therapy: Rationale, design, and study protocol for a multicenter randomized controlled trial (SAFE-AF). Am Heart J. 2025 Dec;290:268-277. doi: 10.1016/j.ahj.2025.07.011. Epub 2025 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivaroxaban	Other / unclassified	10 mg	Oral
Subject	Rivaroxaban	Other / unclassified	15 mg	Oral
Subject	Rivaroxaban	Other / unclassified	20 mg	Oral

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Summary

Timeline

Publications

Drugs

Indications